Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

PHASE2CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

November 29, 2023

Study Completion Date

April 24, 2024

Conditions
Wet Age-related Macular Degeneration
Interventions
DRUG

EYP-1901

Intravitreal Injection

DRUG

Aflibercept 2mg/0.05mL Inj,Oph

Intravitreal Injection

Trial Locations (67)

11021

EyePoint Investigative Site, Great Neck

11788

EyePoint Investigative Site, Hauppauge

11967

EyePoint Investigative Site, Shirley

13088

EyePoint Investigative Site, Liverpool

20186

EyePoint Investigative Site, Warrenton

21117

EyePoint Investigative Site, Owings Mills

21209

EyePoint Investigative Site, Baltimore

21740

EyePoint Investigative Site, Hagerstown

22031

EyePoint Investigative Site, Fairfax

24502

EyePoint Investigative Site, Lynchburg

27587

EyePoint Investigative Site, Wake Forest

28803

EyePoint Investigative Site, Asheville

29169

EyePoint Investigative Site, West Columbia

29414

EyePoint Investigative Site, Charleston

30060

EyePoint Investigative Site, Marietta

32503

EyePoint Investigative Site, Pensacola

32901

EyePoint Investigative Site, Melbourne

33067

EyePoint Investigative Site, Coral Springs

33143

EyePoint Investigative Site, Miami

33609

EyePoint Investigative Site, Tampa

33711

EyePoint Investigative Site, St. Petersburg

33761

EyePoint Investigative Site, Clearwater

33805

EyePoint Investigative Site, Lakeland

33880

EyePoint Investigative Site, Winter Haven

34239

EyePoint Investigative Site, Sarasota

37203

EyePoint Investigative Site, Nashville

38138

EyePoint Investigative Site, Germantown

46290

EyePoint Investigative Site, Carmel

49446

EyePoint Investigative Site, Grand Rapids

50266

EyePoint Investigative Site, West Des Moines

55416

EyePoint Investigative Site, Saint Louis

60439

EyePoint Investigative Site, Lemont

60616

EyePoint Investigative Site, Chicago

63128

EyePoint Investigative Site, St Louis

72762

EyePoint Investigative Site, Springdale

75075

EyePoint Investigative Site, Plano

75231

EyePoint Investigative Site, Dallas

77025

EyePoint Investigative Sites, Houston

77384

EyePoint Investigative Site, The Woodlands

78240

EyePoint Investigative Site, San Antonio

78503

EyePoint Investigative Site, McAllen

78750

EyePoint Investigative Sites, Austin

79606

EyePoint Investigative Site, Abilene

80228

EyePoint Investigative Site, Lakewood

84107

EyePoint Investigative Site, Salt Lake City

85053

EyePoint Investigative Site, Phoenix

89502

EyePoint Investigative Site, Reno

90211

EyePoint Investigative Site, Beverly Hills

91107

EyePoint Investigative Site, Pasadena

91203

EyePoint Investigative Site, Glendale

91436

EyePoint Investigative Site, Encino

92064

EyePoint Investigative Site, Poway

92373

EyePoint Investigative Site, Redlands

92647

EyePoint Investigative Site, Huntington Beach

92697

EyePoint Investigative Site, Irvine

92835

EyePoint Investigative Site, Fullerton

94598

EyePoint Investigative Site, Walnut Creek

95008

EyePoint Investigative Site, Campbell

95825

EyePoint Investigative Site, Sacramento

96701

EyePoint Investigative Site, ‘Aiea

97239

EyePoint Investigative Site, Portland

97401

EyePoint Investigative Site, Eugene

97488

EyePoint Investigative Site, Springfield

98383

EyePoint Investigative Site, Silverdale

02114

EyePoint Investigative Site, Boston

01107

EyePoint Investigative Site, Springfield

07666

EyePoint Investigative Site, Teaneck

Sponsors
All Listed Sponsors
lead

EyePoint Pharmaceuticals, Inc.

INDUSTRY

NCT05381948 - Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) | Biotech Hunter | Biotech Hunter